Vnitr Lek 2015, 61(9):821-828

Myopathy in patients with Waldenström's macroglobulinemia. A case study and an overview of autoimmune expressions of type IgM monoclonal immunoglobulins

Zdeněk Adam1,*, Jarmila Kissová1, Luděk Pour1, Marta Krejčí1, Eva Ševčíková1, Renata Koukalová2, Zdeňka Čermáková3, Marta Černá4, Zdeněk Král1, Jiří Mayer1
1 Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc.
2 Oddělení nukleární medicíny, pracoviště pozitronové emisní tomografie, Masarykův onkologický ústav, Brno, prim. MUDr. Zdeněk Řehák, Ph.D.
3 Oddělení klinické biochemie FN Brno, pracoviště Bohunice, a Katedra laboratorních metod LF MU, Brno, přednosta doc. MUDr. Milan Dastych, CSc., MBA
4 Hematologicko transfuzní oddělení Uherskohradišťské nemocnice, a.s., Uherské Hradiště, prim. MUDr. Marta Černá

In rare cases, monoclonal immunoglobulins bind to intrinsic antigens whereby causing autoimmune damage to the body. The text describes Waldenström's macroglobulinemia which was manifested by muscle pain and anemia. The female patient had suffered from back pain for about 3 years before she came to our clinic. In the last year pain in the muscles of the upper and lower extremities developed in addition to back pain. This led to the suspicion of polymyositis. However this was not confirmed by a special examination. The patient was diagnosed with clearly established infiltration of lymphoplasmacytic lymphoma and 10.8 g/l of type IgM monoclonal immunoglobulin in the bone marrow. Serum myoglobin levels and serum CK activity were repeatedly significantly increased. Therefore the treatment with anti-CD20 monoclonal antibody (Mabthera) 375 mg/m2 i. v. was started, administered once a month, with cyclophosphamide 500 mg/m2 i. v. on days 1 and 15 of a 28-day cycle, and dexamethasone 20 mg from 1st through to 4th days and 15th through to 18th days of the treatment cycle. There were 8 cycles planned. Already after a 5th cycle, the disappearance of monoclonal immunoglobulin (negative immunofixation), normalisation of myoglobin and CK values and significant relief from muscle pain were achieved. The hemoglobin concentrations before treatment were significantly reduced, while they were normalised after treatment. After 5 cycles, the complete remission of Waldenström's disease was reached according to biochemical parameters, and normalisation of the serum myoglobin and creatine kinase levels was achieved.

Keywords: Mabthera; myopathy; type IgM monoclonal immunoglobulin; Waldenström's macroglobulinemia

Received: December 3, 2014; Accepted: April 20, 2015; Published: September 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adam Z, Kissová J, Pour L, Krejčí M, Ševčíková E, Koukalová R, et al.. Myopathy in patients with Waldenström's macroglobulinemia. A case study and an overview of autoimmune expressions of type IgM monoclonal immunoglobulins. Vnitr Lek. 2015;61(9):821-828.
Download citation

References

  1. Dighiero G, Guilbert B, Fermand JP et al. Thirty-six human monoclonal immunoglobulins with antibody activity against cytoskeleton proteins, thyroglobulin, and native DNA: immunologic studies and clinical correlations. Blood 1983; 62(2): 264-270. Go to original source...
  2. Avrameas S, Guilbert B, Dighiero G. Natural antibodies against tubulin, actin myoglobin, thyroglobulin, fetuin, albumin and transferrin are present in normal human sera, and monoclonal immunoglobulins from multiple myeloma and Waldenström's macroglobulinemia may express similar antibody specificities. Ann Immunol (Paris) 1981; 132C(2): 231-236. Go to original source... Go to PubMed...
  3. Al-Lozi M, Pestronk A. Organ-specific autoantibodies with muscle weakness. Curr Opin Rheumatol 1999; 11(6): 483-488. Go to original source... Go to PubMed...
  4. Bulikova A, Smejkal P, Zavřelová J at al. Získané inhibitory krevního srážení. Interní medicína pro praxi 2008; 10(7): 336-339.
  5. Triplett DA. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. J Autoimmun 2000; 15(2): 173-178. Go to original source... Go to PubMed...
  6. Carlizzi G, Ciarla MV, Diluzio A et al. Autoantibodies in patients with monoclonal gammopathies. Ann N.Y. Acad Sci 2007; 1107: 206-211. Go to original source... Go to PubMed...
  7. Stone MJ, McElroy A, Pestronk P et al. Human monoclonal macroglobulins with anbody activity. Semin Oncol 2003; 30(2): 318-324. Go to original source... Go to PubMed...
  8. Stone MJ, Marlini V, Pascual P. Autoantibody activity in Waldenström's macroglobulinaemia. Clin Lymphoma 2005; 5(4): 225-229. Go to original source... Go to PubMed...
  9. Antienza J, Bockorn B, Dadla A et al. Inflammatory and immune-releated condition associated with Waldenström's macroglobulinemia. A single center experience. Leukemia and Lymphoma 2015; 56(4): 1179-1180. Go to original source... Go to PubMed...
  10. Ansell SM. Waldenström Macroglobulinemia and autoimmunity: what's the connection? Leukemia Lymphoma 2015; 56(4): 845-846. Go to original source... Go to PubMed...
  11. Jonsson V, Kierkegaard A, Salling S et al. Autoimmunity in Waldenström's macroglobulinemia. Leukemia Lymphoma 1999; 34(3-4): 373-379. Go to original source... Go to PubMed...
  12. Christenson W, Dacie J. Serum proteins in acquired hemolytic anemia (autoantibody type). Brit J Haematol 1957; 3(2): 153-164. Go to original source... Go to PubMed...
  13. Adam Z, Pejchalová A, Chlupová G. Nemoc chladových aglutininů nereagující na léčbu glukokortikoidy a na léčbu rituximabem. Jaký postup zvolit pro třetí linii léčby? Popis případu a přehled literatury. Vnitř Lék 2013; 59(9): 828-840. Go to PubMed...
  14. Kritzman J, Kunkel H, McCarthy J et al. Studie of a Waldenström-type macroglobulinemia with revmatoid factor properties. J Lab Clin Med 1961; 57: 905-917.
  15. Adam Z, Králová E. Kryoglobulinémie - první příznak mnohočetného myelomu. Klin Onkol 1992; 5(5): 147-148.
  16. Husa P, Adam Z, Husová E et al. Léčba chronické infekce virem hepatitidy C pegylovaným interferonem a ribavirinem u pacienta se smíšenou kryoglobulinémií. Vnitř Lék 2005; 51(2): 238-243.
  17. Dellagi K, Brouet J Danon F. Gross idiotype antigens among monoclonal imunoglobulin M from patients with Waldenström's macroglobulinemia and polyneuropathy. J Clin Incest 1979; 64(5): 1530-1534. Go to original source... Go to PubMed...
  18. Adam Z, Šmardová J, Ščudla. V Waldenströmova makroglobulinemie - klinické projevy, diferenciální diagnostika a prognóza nemoci. Vnitř Lék 2007; 53(12): 1325-1337. Go to PubMed...
  19. Adam Z, Pour L, Krejčí M et al. Poškození ledvin při mnohočetném myelomu a dalších monoklonálních gamapatiích. Vnitř Lék 2008; 54(9): 847-861. Go to PubMed...
  20. Adam Z, Krejčí M, Pour L et al. Schnitzlerův syndrom - popis čtrnáctiletého průběhu nemoci a přehled informací o této nemoci. Vnitř Lék 2008; 54(12): 1140-1153. Go to PubMed...
  21. Adam Z, Feit J, Krejčí M et al. IgA pemphigus provázející mnohočetný myelom vymizel při léčbě bortezomibem (Velcade), cyklofosfamidem a dexametazonem. Popis případu a přehled literatury. Vnitř Lék 2009; 55(10): 981-991. Go to PubMed...
  22. Adam Z, Zahradová L, Krejčí M et al. Difuzní plošná normolipemická xantomatóza a nekrobiotický xantogranulom, asociované s monoklonální gamapatií - přínos PET-CT pro stanovení rozsahu nemoci a zkušenosti s léčbou. Popis dvou případ a přehled literatury. Vnitř Lék 2010; 56(11): 1159-1168.
  23. Adam Z, Szturz P, Pour L et al. Kožní projevy monoklonálních gamapatií, zkušenosti jednoho pracoviště. Čes Dermatoven 2011; 1(2): 30-37.
  24. Szturz P, Adam Z, Vašků V et al. Complete remission of multiple myeloma associated sclerodema after bortezomib-based treatment. Leuk Lymphoma 2013; 54(6): 1324-1326. Go to original source... Go to PubMed...
  25. Mak WM, Chen PL, Lee K. Misleading hypercalcaemia in a patient with Waldenstrom's macroglobulinaemia. Br J Biomed Sci 2011; 68(4): 210-212. Go to original source... Go to PubMed...
  26. Elfatih A, Anderson NR, Fahie-Wilson MN et al. Pseudo-pseudohypercalcaemia, apparent primary hyperparathyroidism and Waldenström's macroglobulinaemia. J Clin Pathol 2007; 60(4): 436-437. Go to original source... Go to PubMed...
  27. Side L, Fahie-Wilson MN, Mills MJ. Hypercalcaemia due to calcium binding IgM paraprotein in Waldenström's macroglobulinaemia. J Clin Pathol 1995; 48(10): 961-962. Go to original source... Go to PubMed...
  28. al-Lozi MT, Pestronk A, Yee WC et al. Myopathy and paraproteinemia with serum IgM binding to a high-molecular-weight muscle fiber surface protein. Ann Neurol 1995; 37(1):41-46. Go to original source... Go to PubMed...
  29. Bakri K, Haydar AA, Davis J et al. Waldenström's macroglobulinaemia presenting as isolated epistaxis: a common complaint but a rare cause. Int J Clin Pract 2004; 58(1): 81-82. Go to original source... Go to PubMed...
  30. Deconinck N, Laterre EC, Van den Bergh PY. Adult-onset nemaline myopathy and monoclonal gammopathy: a case report. Acta Neurol Belg 2000; 100(1): 34-40. Go to PubMed...
  31. Eymard B, Brouet JC, Collin H et al. Late-onset rod myopathy associated with monoclonal gammopathy. Neuromuscul Disord 1993; 3(5-6): 557-560. Go to original source... Go to PubMed...
  32. Islam A, Myers K, Cassidy DM et al. Muscle Involvement in Multiple Myeloma: Report of a Patient Presenting Clinically as Polymyositis. Hematology 1999; 4(2):123-125. Go to original source... Go to PubMed...
  33. Keller CE, Hays AP, Rowland LP et al. Adult-onset nemaline myopathy and monoclonal gammopathy. Arch Neurol 2006; 63(1): 132-134. Go to original source... Go to PubMed...
  34. Bockorny B, Atienza J, Dasanu CA. Autoimmune manifestation in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2014; 14(6): 456-549. Go to original source... Go to PubMed...
  35. Adam Z, Hájek R, Krejčí M et al. Diagnostika a léčba Waldenströmovy makroglobulinémie. Transfuze a hematologie dnes 2014; 20(Suppl): 7-22.
  36. Dimopoulos MA, Gastritis E, Owen RG et al. Treatment recommendation for patients with Waldenström macroglobulinemia and releated disorders. Blood 2014; 124(9): 1404-1411. Go to original source... Go to PubMed...
  37. Castillo JJ, Olszewski AJ, Kanan S et al. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol 2015; 169(1): 81-89. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.